Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Mycophenolate Mofetil for the Treatment of HTLV-1 Associated Myelopathy: A Case Report
Infectious Disease
P11 - Poster Session 11 (11:45 AM-12:45 PM)
4-003

HTLV-1 Associated Myelopathy/Tropical Spastic Paresis (HAM/TSP) is a progressive, inflammatory neurological disorder caused by the HTLV-1 retrovirus. Current treatment options for HAM/TSP are limited. We report a case of a patient with rapidly progressive HAM/TSP who has had significant, sustained improvement with mycophenolate mofetil (MMF) over 16 months. To our knowledge, this is the first reported case of HAM/TSP with a prolonged clinical response to MMF.

NA

NA

A 65 year-old female presented with 2 months of progressive bilateral leg weakness and paresthesias. Within 6 months of symptom onset, the patient reported urinary incontinence and required a wheelchair for mobility. Her initial neurological exam demonstrated predominantly proximal, bilateral lower limb weakness, bilateral lower limb hyperreflexia, spasticity, and loss of vibration sense. Her Osame motor disability score (OMDS) within a month of presentation was 9 (range 0-13). Brain and spine MRIs with and without contrast were unremarkable. Further work-up revealed HTLV-1/2 antibodies in cerebrospinal fluid, and she was diagnosed with HAM/TSP. She demonstrated an initial robust response to corticosteroids with a reduction in her OMDS to 5, but had a marked decline in mobility with attempts to taper steroids. MMF was initiated, enabling prednisone to be reduced to a modest maintenance dose. On this regimen, she had significant clinical improvement, with a sustained reduction in her OMDS to 3 over 16 months of follow up. She experienced resolution of her urinary incontinence and improved strength, regaining the ability to ambulate without assistance.

The pathogenesis of HAM/TSP involves T-cell mediated inflammation of the spinal cord. Our case suggests that MMF may be an effective disease modifying therapy in the treatment of HAM/TSP. This robust benefit of MMF may result from its induction of T cell apoptosis and disruption of clonal proliferation of activated T cells.

Authors/Disclosures
Alexandra A. Mandel
PRESENTER
Miss Mandel has nothing to disclose.
Sofia Chernet, MD (Northwestern) Miss Chernet has nothing to disclose.
Pritha Ghosh, MD (George Washington Medical Faculty Associates) Dr. Ghosh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for New Touch Digital.
Henry J. Kaminski, MD, FAAN (George Washington University) The institution of Dr. Kaminski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Kaminski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Kaminski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cabaletta Bio. Dr. Kaminski has stock in ARC Biotechnology. The institution of Dr. Kaminski has received research support from National Institutes of Health. Dr. Kaminski has received publishing royalties from a publication relating to health care.